Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS trial of ziltivekimab versus placebo for cardiovascular outcomes in patients with ASCVD, chronic kidney disease, and systemic inflammation
MOH_2021-06-29_010091Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD) and chronic inflammation comparing ziltivekimab with placebo (2 arms). Started Jun 2021; status: completed.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)chronic inflammation
Beyond the preview
Go deeper on MOH_2021-06-29_010091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-29_010091.